Biochemistry
|
Molecular mass |
6.000 Da |
|
Bioavailability |
100% after subcutaneous injection |
|
Peak concentration |
4-5 after drug administration |
|
Half-life |
25 hours |
Danaparoid Sodium (Orgaran®) is an anticoagulant drug from the group of heparinoids preventing coagulation similar to heparin. It enhances the inhibitory activity of antithrombin. It consists of a mixture of glycosaminoglycans, derived from animal intestinal mucosa.
Clinical significance
Danaparoid Sodium (Orgaran ® ) is used as an alternative anticoagulant drug for patients that cannot be treated with heparins e.g. due to a heparin induced thrombocytopenia (HIT) type II. Correlation of anti-factor Xa activity and administered dose of Orgaran is linear.
If monitoring of anticoagulation therapy or an individual dose setting is necessary, a functional anti-factor Xa chromogenic assay (e.g. Technochrom ® anti-Xan) should be used. In this assay, plasma spiked with Orgaran ® has to be used for generation of a standard curve.
Indication
- Prevention of deep vein thrombosis in situations, where heparin should not be applied, including patients with heparin-induced thrombocytopenia (HIT) type II
- Treatment of thromboembolic disorders in patients who require urgent parenteral anticoagulation because of the development or history of heparin-induced thrombocytopenia (HIT) type II
Literature
- Fachinformation Orgaran ® der Aspen Pharma Trading Ltd. Stand Juli 2014
- Schuster B. Monitoring of anticoagulants. Hämostaseologie 29, 268-273, 2009
- Alban S. Pharmakologie der Heparine und direkten Antikoagulanzien Hämostaeologie 28: 400-420, 2008.